Blog

As regenerative medicine continues to expand in clinical relevance, 2026 is shaping up to be a breakthrough year for biologic-based therapies. From orthopedic applications to aesthetic innovations, more providers are turning to regenerative solutions like Wharton’s Jelly  and exosome therapy  to improve patient outcomes. But with innovation comes responsibility. Not all biologics are created equal—and the key to success lies in one critical factor: sourcing . Why Sourcing is

Introduction: More Than Just Sourcing—A Commitment to Quality In regenerative medicine, the integrity of every product is critical. At PB...